MedTrace Logo

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

NCT07037758 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 380

Last updated 2026-03-27

No results posted yet for this study

Summary

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248.

The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Conditions

Interventions

DRUG

Tarlatamab

Administered as an IV infusion.

DRUG

AB248

Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.

Sponsors & Collaborators

  • Asher Biotherapeutics, Inc.

    collaborator INDUSTRY

  • Amgen

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-16
Primary Completion
2028-03-18
Completion
2031-01-18
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07037758 on ClinicalTrials.gov